These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15309880)

  • 1. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.
    Ponce J; Argüello L; Bastida G; Ponce M; Ortiz V; Garrigues V
    Dig Dis Sci; 2004 Jun; 49(6):931-6. PubMed ID: 15309880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
    Bytzer P; Blum A; De Herdt D; Dubois D;
    Aliment Pharmacol Ther; 2004 Jul; 20(2):181-8. PubMed ID: 15233698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
    Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
    Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
    Liu XH; Ke MY; Song ZQ; Luo JY; Yuan YZ; Hou XH; Zhu YL; Sun J; Zha H
    Zhonghua Nei Ke Za Zhi; 2005 Nov; 44(11):818-21. PubMed ID: 16316559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A; Breiter J; Perdomo C; Barth J
    Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
    Miner P; Orr W; Filippone J; Jokubaitis L; Sloan S
    Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of rabeprazole once daily for acid-related disorders.
    Lanza F; Bardhan KD; Perdomo C; Niecestro R; Barth J
    Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment].
    Yang XL; Liu XH; Ke MY; Song ZQ; Yuan YZ; Luo JY; Hou XH
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2404-7. PubMed ID: 20137694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment.
    Bour B; Staub JL; Chousterman M; Labayle D; Nalet B; Nouel O; Pariente A; Tocque E; Bonnot-Marlier S
    Aliment Pharmacol Ther; 2005 Apr; 21(7):805-12. PubMed ID: 15801915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.
    Damiano A; Siddique R; Xu X; Johanson J; Sloan S
    Dig Dis Sci; 2003 Apr; 48(4):657-62. PubMed ID: 12741452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
    Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group.
    Birbara C; Breiter J; Perdomo C; Hahne W
    Eur J Gastroenterol Hepatol; 2000 Aug; 12(8):889-97. PubMed ID: 10958216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
    Johnson M; Guilford S; Libretto SE;
    Curr Med Res Opin; 2002; 18(5):303-10. PubMed ID: 12240793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire.
    Shikiar R; Flood E; Siddique R; Howell J; Dodd SL
    Dig Dis Sci; 2005 Nov; 50(11):2025-33. PubMed ID: 16240210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
    Caos A; Moskovitz M; Dayal Y; Perdomo C; Niecestro R; Barth J
    Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.